AnaptysBio Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van AnaptysBio is gedaald met een gemiddeld jaarlijks percentage van -24.9%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.1%. De inkomsten zijn daalde met een gemiddeld percentage van 5.7% per jaar.

Belangrijke informatie

-24.9%

Groei van de winst

-24.9%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	-5.7%
Rendement op eigen vermogen	-196.4%
Nettomarge	-289.8%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching

Nov 21

AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

Nov 07

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 22

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Feb 22

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Oct 10

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 24

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Apr 27

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Jan 10

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Oct 05

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Sep 14

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Sep 12

AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

Sep 01

AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%

Aug 31

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

Aug 08

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

May 10

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Mar 16

AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

Nov 11

Opbrengsten en kosten

Hoe AnaptysBio geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:ANAB Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Sep 24	57	-166	42
30 Jun 24	30	-170	42
31 Mar 24	23	-163	43
31 Dec 23	17	-164	42
30 Sep 23	15	-148	41
30 Jun 23	13	-144	37
31 Mar 23	11	-137	37
31 Dec 22	10	-129	33
30 Sep 22	4	-135	29
30 Jun 22	24	-108	29
31 Mar 22	53	-76	23
31 Dec 21	63	-58	21
30 Sep 21	122	8	21
30 Jun 21	101	-9	21
31 Mar 21	71	-30	20
31 Dec 20	75	-20	19
30 Sep 20	18	-74	18
30 Jun 20	18	-81	17
31 Mar 20	23	-84	16
31 Dec 19	8	-97	16
30 Sep 19	5	-94	16
30 Jun 19	10	-79	16
31 Mar 19	5	-69	16
31 Dec 18	5	-62	16
30 Sep 18	8	-52	14
30 Jun 18	3	-45	13
31 Mar 18	10	-34	11
31 Dec 17	10	-30	9
30 Sep 17	10	-27	8
30 Jun 17	13	-19	6
31 Mar 17	12	-15	5
31 Dec 16	17	-4	4
30 Sep 16	18	-4	4
30 Jun 16	19	-4	4
31 Mar 16	18	-6	4
31 Dec 15	18	-5	4
30 Sep 15	17	-2	3
30 Jun 15	19	0	3
31 Mar 15	18	1	3
31 Dec 14	16	0	2
31 Dec 13	5	-6	2

Kwaliteitswinsten: ANAB is momenteel verliesgevend.

Groeiende winstmarge: ANAB is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: ANAB is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 24.9% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van ANAB over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: ANAB is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: ANAB heeft een negatief Return on Equity ( -196.35% ), omdat het momenteel verliesgevend is.

AnaptysBio Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Consensus revenue estimates increase by 70%

AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs

Chief Legal Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

Consensus revenue estimates fall by 20%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target increased by 10% to US$48.22

AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

New minor risk - Shareholder dilution

Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

Consensus revenue estimates increase by 48%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

No longer forecast to breakeven

Price target increased by 27% to US$35.83

President exercised options and sold US$150k worth of stock

Consensus revenue estimates increase by 27%

No longer forecast to breakeven

New minor risk - Profitability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 16%

Price target decreased by 10% to US$26.80

Price target decreased by 12% to US$28.20

AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Chief Financial Officer exercised options and sold US$116k worth of stock

AnaptysBio, Inc. Announces Board Changes

High number of new directors

Consensus revenue estimates decrease by 18%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

AnaptysBio, Inc. and GSK-Partner Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approved in U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Forecast to breakeven in 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates fall by 43%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2025

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

AnaptysBio, Inc. (NasdaqGS:ANAB) announces an Equity Buyback for $50 million worth of its shares.

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio Announces Portfolio

Anaptysbio- and GSK-Partnered Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Meets Primary Endpoint in Phase 3 Ruby Trial in Primary Advanced or Recurrent Endometrial Cancer

Consensus forecasts updated

Price target increased to US$31.50

Price target increased to US$31.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Anaptysbio and Gsk-Partnered Immuno-Oncology Agents Jemperli (Dostarlimab-Gxly) and Cobolimab Show Positive Progress in Two Separate Non-Small Cell Lung Cancer Trials

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Consensus revenue estimates increase by 58%

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Consensus revenue estimates increase by 17%

Price target decreased to US$29.33

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Consensus revenue estimates fall by 10%

AnaptysBio, Inc. Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa